Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 19982006: Factors associated with improved survival outcome

Leukemia and Lymphoma

Volumn 52, Issue 9, 2011, Pages 1727-1735

  Nivison Smith, Ian ^a   Dodds, Anthony J ^b   Doocey, Richard ^c   Ganly, Peter ^d   Gibson, John ^e   Ma, David D F ^b   Simpson, Judy M ^f   Szer, Jeff ^g   Bradstock, Kenneth F ^h  

^a Australasian Bone Marrow Transplant Recipient Registry (ABMTRR)   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d CHRISTCHURCH HOSPITAL   (New Zealand)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

Author keywords

hematopoietic cell transplant; multiple myeloma; Reduced intensity conditioning

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; HLA ANTIGEN; IMMUNOGLOBULIN G; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THALIDOMIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT; ARTICLE; CANCER SURVIVAL; CELL TRANSPLANTATION; FEMALE; HEMATOPOIETIC CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; WHOLE BODY RADIATION;

ADULT; AUSTRALIA; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEW ZEALAND; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 80052047456     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.582201     Document Type: Article

References (26)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111: 2962-2972.
2. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996;88:2787-2793. (Pubitemid 26327535)
3. Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113:209-216. (Pubitemid 32423325)
4. Reynolds C, Ratanatharathorn V, Adams P, et al. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 2001;27:801-807. (Pubitemid 32496412)
5. Mohty M, Boiron JM, Damaj G, et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004;34:77-84. (Pubitemid 39022961)
6. Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004;103:4362-4364. (Pubitemid 38685385)
7. Ballen KK, King R, Carston M, et al. Outcome of unrelated transplants in patients with multiple myeloma. Bone Marrow Transplant 2005;35:675-681. (Pubitemid 40520952)
8. Crawley C, Iacobelli S, Björkstrand B, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588-3594. (Pubitemid 46572554)
9. Georges GE, Maris MB, Maloney DG, et al. Nonmyeloa-blative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007;13:423-432. (Pubitemid 46421886)
10. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005;105: 4532-4539. (Pubitemid 40720805)
11. Lee C-K, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003;31:73-80. (Pubitemid 36110532)
12. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allo-transplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574-2579.
13. Majolino I, Davoli M, Carnevalli E, et al. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma 2007;48:759-766. (Pubitemid 46605549)
14. de Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008; 41:953-960. (Pubitemid 351850499)
15. Nivison-Smith I, Bradstock KF, Dodds AJ, et al. Hemato-poietic stem cell transplantation in Australia and New Zealand,1992-2004. Biol Blood Marrow Transplant 2007; 13:905-912. (Pubitemid 47055384)
16. Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473. (Pubitemid 44264086)
17. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-828.
18. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:177-179.
19. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706. (Pubitemid 29126745)
20. Bruno B, Rotta M, Patriarca F, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma:the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009;113:3375-3382.
21. Rotta M, Storer BE, Sahebi F, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoie-tic cell transplantation and nonmyeloablative allografting. Blood 2009;113:3383-3391.
22. Efebera YA, Qureshi SR, Cole SM, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant 2010;16: 1122-1129.
23. Majolino I, Corradini P, Scimè R, et al. High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. Bone Marrow Transplant 2003;31:767-773. (Pubitemid 36656669)
24. Kröger N, Shimoni A, Schilling G, et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol 2010;148:323-331.
25. Kumar S, Shrestha S, Zhang M-J, et al. Allogeneic stem cell transplantation (SCT) for multiple myeloma (MM)-what has changed? A CIBMTR analysis from 1989-2005. Blood 2009;114(Suppl. 1): Abstract 54.
26. Lokhorst H, Einsele H, Vesole D, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010;28:4521-4530.